Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications

JAMA

Volumn 293, Issue 19, 2005, Pages 2372-2383

  Moses Kolko, Eydie L ^a   Bogen, Debra ^a   Perel, James ^a   Bregar, Amy ^b   Uhl, Kathleen ^c   Levin, Bob ^c   Wisner, Katherine L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERBUTALINE; THIORIDAZINE; TRAZODONE; VENLAFAXINE;

AGITATION; BEHAVIOR DISORDER; CLINICAL FEATURE; COHORT ANALYSIS; CRYING; DECISION MAKING; DRUG LABELING; DRUG MANUFACTURE; ENVIRONMENTAL EXPOSURE; FEEDING DISORDER; FOOD AND DRUG ADMINISTRATION; GESTATION PERIOD; HUMAN; HYPERREFLEXIA; HYPOTHERMIA; IRRITABILITY; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; NEONATAL BEHAVIORAL SYNDROME; NEWBORN DEATH; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SHIVERING; SIDE EFFECT; SOMNOLENCE; TACHYPNEA; THIRD TRIMESTER PREGNANCY; TREMOR; UTERUS; VOMITING; CHEMICALLY INDUCED DISORDER; CHILD BEHAVIOR; DRUG EFFECT; FEMALE; GESTATIONAL AGE; NEWBORN; NEWBORN DISEASE; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE; RISK ASSESSMENT; SYNDROME;

FEMALE; GESTATIONAL AGE; HUMANS; INFANT BEHAVIOR; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; PREGNANCY; PREGNANCY OUTCOME; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; SEROTONIN UPTAKE INHIBITORS; SYNDROME;

EID: 18644382386     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.19.2372     Document Type: Review

References (62)

1. Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: Free Press; 1991.
2. Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey, I: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29:85-96.
3. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246-2248.
4. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015.
5. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA. 1998;279:609-610.
6. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol. 1999;55:503-508.
7. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728-1730.
8. Diav-Citrin O, Shechtman S, Weinbaum D, Arnon J, Wajnberg R, Ornoy A. Pregnancy outcome after gestational exposure to paroxetine: a prospective controlled cohort study. Teratology. 2002;65:298.
9. Altshuler LL, Cohen L, Szuba MP, Burt VK, Gitlin M, Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153:592-606.
10. Effexor (venlafaxine hydrochloride) tablets prescribing information. Available at: http://www.fda.gov/medwatch/SAFETY/2004/may_PI/Effexor_PI.pdf. Accessed September 2, 2004.
11. Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry. 2000;157:1933-1940.
12. Stiskal JA, Kulin N, Koren G, Ho T, Ito S. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed. 2001;84:F134-F135.
13. Nijhuis IJ, Kok-Van Rooij GW, Bosschaart AN. Withdrawal reactions of a premature neonate after maternal use of paroxetine. Arch Dis Child. 2001;84:F77.
14. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry. 1997;171:391-392.
15. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90:288-291.
16. Gerola O, Fioccchi S, Rondini G. Rischi da farmaci antidepressivi in gravidanza: revisione della letteratura e presentazione di un caso di sospetta syndrome da astinenza da paroxetina in neonato. Riv Ital Pediatri. 1999;25:216-218.
17. Herbst F, Gortner L. Paroxetine withdrawal syndrome as differential diagnosis of acute neonatal encephalopathy? [in German] Z Geburtshilfe Neonatol. 2003;207:232-234.
18. Kent LS, Laidlaw JD. Suspected congenital sertraline dependence. Br J Psychiatry. 1995;167:412-413.
19. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 1993;92:721-722.
20. Mhanna MJ, Bennet JB II, Izatt SD. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics. 1997;100:158-159.
21. Mohan CG, Moore JJ. Fluoxetine toxicity in a preterm infant. J Perinatol. 2000;20:445-446.
22. Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr (Phila). 2001;40:681-684.
23. de Moor RA, Mourad L, ter Haar J, Egberts AC. Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy. Ned Tijdschr Geneeskd. 2003;147:1370-1372.
24. Verghese C, DeLeon J, Nair C, Simpson GM. Clozapine withdrawal effects and receptor profiles of typical and atypical neuroleptics. Biol Psychiatry. 1996;39:135-138.
25. Laine K, Heikkinin T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60:720-726.
26. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther. 2003;73:330-337.
27. Oesterheld JR. A review of developmental aspects of cytochrome P450. J Child Adolesc Psychopharmacol. 1998;8:161-174.
28. Kearns GL, Abdel-Rahman SM, Alander SW, Blowery DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action, and therapy in infants in children. N Engl J Med. 2003;349:1157-1167.
29. Fox E, Balis FM. Drug therapy in neonates and pediatric patients. In: Atkinson AJ, Daniels CE, Dedrick RL, Grudzinskas CV, Markey SP, eds. Principles of Clinical Pharmacology. San Diego, Calif: Academic Press; 2001:293-305.
30. CDER 2004 meeting documents. Available at: http://www.fda.gov/ohrms/ dockets/ac/cder04.html#Anti-Infective. Accessed September 1, 2004.
31. Sanz EJ, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet. 2005;365:482-487.
32. Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Psychiatry. 1997;58(suppl 7):23-27.
33. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry. 2000;48:996-1000.
34. Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn. J Clin Psychopharmacol. 1995;15:417-420.
35. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156:1129-1132.
36. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry. 2004;65:230-237.
37. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med. 2004;158:312-316.
38. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113:368-375.
39. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry. 2003;160:993-996.
40. Misri S, Oberlander TF, Fairbrother N, et al. Relation between prenatal maternal mood and anxiety and neonatal health. Can J Psychiatry. 2004;49:684-689.
41. Hegerl U, Bottlender R, Callinat J, Kuss HJ, Ackenheil M, Moller HJ. The Serotonin Syndrome Scale: first results on validity. Eur Arch Psychiatry Clin Neurosci. 1998;248:96-103.
42. Norton JD. Findings from selective serotonin reuptake inhibitor-exposed neonates should be interpreted with caution. Pediatrics. 2004;114:1739-1740.
43. Field T. Infants of depressed mothers. Infant Behav Dev. 1995;18:1-13.
44. Oberlander TF, Grunau RE, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res. 2002;51:443-452.
45. American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 1998;107:1079-1088.
46. Haddad PM. Antidepressant discontinuation syndromes: clinical relevance, prevention, and management. Drug Saf. 2001;24:183-197.
47. Wisner KL, Perel LM, Findling RL. Antidepressant treatment during breast-feeding. Am J Psychiatry. 1996;153:1132-1137.
48. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. The use of psychotropic medications during breast-feeding. Am J Psychiatry. 2001;158:1001-1009.
49. Morselli PL, Franco-Morselli R, Bossi L. Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications. Clin Pharmacokinet. 1980;5:485-527.
50. Meltzer HY, Young M, Metz J, Fang VS, Schyve PM, Arora RC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm. 1979;45:165-175.
51. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705-713.
52. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol. 1997;17:208-221.
53. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16:356-362.
54. Blier P, Ward NM. Is there a role for 5HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53:193-203.
55. Wisner KL, Perel JM. Psychopharmacologic agents and electroconvulsive therapy during pregnancy and the puerperium. In: Cohen RL, ed. Psychiatric Consultation in Childbirth Settings. New York, NY: Plenum Press; 1988:165-206.
56. Schmidt K, Olesen OV, Jensen PN. Citalopram and breast-feeding: serum concentration and side effects in the infant. Biol Psychiatry. 2000;47:164-165.
57. Charpak N, Ruiz-Pelaez JG, Figueroa de Calume Z. Current knowledge of kangaroo mother intervention. Curr Opin Pediatr. 1996;8:108-112.
58. Anderson GC, Moore E, Hepworth J, Bergman N. Early skin-to-skin contact for mothers and their healthy newborn infants. Cochrane Database Syst Rev. 2003 (2):CD003519.
59. Department of Reproductive Health and Research, World Health Organization. Kangaroo Mother Care: A Practical Guide. Geneva, Switzerland: World Health Organization; 2003. Available at: http://www.who.int/reproductive- health/publications/kmc/. Accessed August 7, 2003.
60. Finnegan LP, Kron RE, Connaughton JF Jr, Emich JP Jr. A scoring system for evaluation and treatment of the neonatal abstinence syndrome: a new clinical and research tool. In: Morselli PL, Garattini S, Sereni F, eds. Basic and Therapeutic Aspects of Perinatal Pharmacology. New York, NY: Raven Press; 1975:139-152.
61. Gillman PK. The serotonin syndrome and its treatment J Psychopharmacol. 1999;13:100-109.
62. Hines RN, Adams J, Buck GM, et al. NTP-CERHR Expert Panel report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Res B Dev Reprod Toxicol. 2004;71:193-280.